1、 30 50 30 50 60 2 , A ( 30 ) B ( 50 ) , 30 12 (Hb A1c) (BMI) 12 , A Hb A1c BMI Hb A1c BMI U;B Hb A1c BMI A , (P9% : (1) , 2 , ; (2) ; (3) ; (4) ; (5) ; (6) , A ( 30 ) B ( 50 ) A 16 , 14 , B 15 , 15 , (P0.05) , 1.2 A 30 , 30; 50 mg/ , 3 /d B 50 ( ) , 50 ( ) , 30 50 4.47.0 mmol/L, 2 h 10 mmol/L , 3.9
2、mmol/L 1.3 12 , Hb A1c BMI 1.4 SPSS18.0 , t ; (%) , P0.05 2 12 , A Hb A1c BMI Hb A1c BMI Hb A1c BMI A , (P0.05) 12 , B A mmol/l, (P0.05) A /d, B /d, (P0.05) 3 2 2 h , , Hb A1c , DCCT/EDIC UKPDS , , Hb A1c , , , 1,2 30 50 , , A 30 , 2 /d, , , 30 , , , , , 30 , Hb A1c , 30 B 50 , 1 1 , , , , , , BMI ,
3、 , , 30 50 , , , , 50 30 3 , 2 , 50 30 , 1 -cell function in recent-onset type 2diabetes by Xiaokeping mixture.Chin J Mod Appl Pharm, 2011, 28 (1) :81-84. 2Turner R, Holman R, Cull C, et al.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33) .UK Prospective Diabetes Study (UKPDS) Group.Lancet, 1998, 352 (9131) :837-853. 3 , . 2 39 . , 2012, 10 (4) :567-568.
